

**Materials for this course will release 04/12/2023**

---

**Geriatric Pharmacy Specialty Recertification Literature Study: Module 1A-C (Cert # L239196)**

**Teaser:** The Literature Study Module provides immediate access to peer-selected, contemporary articles that are relevant to specialty practice. After learners review the content, they must successfully complete an online assessment to earn recertification credit.

**Tag:** Certifications; Geriatric



**ACPE Numbers:** Various – see listing below

**Pre-Sale Date:** 03/15/2023

**Content Release Date:** 04/12/2023

**Expiration Dates:** 10/17/2023

**Activity Type:** Application-based

**CE Credits:** 15 contact hours

**Activity Fee:** \$55 (ASHP member); \$110 (non-member)

**Accreditation**



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.



The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

**Target Audience**

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification contact hours to maintain their Board of Pharmacy Specialties (BPS).

**Activity Overview**

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 3 online home study activities (see table below). Each activity is designed to assess the learners' ability to analyze and apply peer-selected contemporary articles to practice.

**Module 1A: Oncology and Immunology:** This module focuses on cancer management in older patients as well as contemporary issues related to vaccines.

**Module 1B: Current topics:** This module focuses on various topics including restless leg syndrome, osteoporosis, cardiovascular disease, and deprescribing in older adults.

**Module 1C: Guideline updates:** This module focuses on recent updates to guidelines for the management of benign prostatic hyperplasia, aspirin use for primary prevention of cardiovascular disease, coronary artery revascularization, and falls in adults with cardiovascular disease.

**Materials for this course will release 04/12/2023**

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP and ACCP professional development program for BCGP recertification approved by the BPS.

#### Recertification Credit\*

Board certified pharmacists are eligible to receive up to 15 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity	ACPE Number	Contact Hours	Assessment Pass Point
Module 1A: Oncology and Immunology	0204-9999-23-962-H01	5.00	TBD
Module 1B: Current Topics	0204-9999-23-963-H01	5.00	TBD
Module 1C: Guideline Updates	0204-9999-23-964-H01	5.00	TBD
<b>Recertification Assessment</b>		15.0 BPS	

#### Articles and Learning Objectives

##### Module 1A: Oncology and Immunology

ACPE#: 0204-9999-23-962-H01

This module focuses on cancer management in older patients as well as contemporary issues related to vaccines.

Novak J, Goldberg A, Dharmarajan K, et al. Polypharmacy in older adults with cancer undergoing radiotherapy: a review. *J Geriatr Oncol.* 2022; 13:778-783.

Learning Objectives:

- Describe polypharmacy in older adults with cancer undergoing radiation therapy.
- Develop recommendations for medication review and optimization of medications to minimize polypharmacy in older adults with cancer undergoing radiation therapy.

Li D, Sun C, Kim H, et al. Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial. *JAMA Oncol.* 2021; 7(11):e214158

Learning Objectives:

- Describe the study by Li and colleagues of geriatric assessment-driven intervention (GAIN) for older adults with cancer receiving chemotherapy.
- Develop recommendations for implementing geriatric assessment-driven intervention (GAIN) for older adults with cancer receiving chemotherapy.

**Materials for this course will release 04/12/2023**

---

Nebhan CA, Cortellini A, et al. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer A Multicenter International Cohort Study. *JAMA Oncol.* 2021; 7(12):1856-1861.

Learning Objectives:

- Describe the study by Nebhan and colleagues of immune checkpoint inhibitor (ICI) therapy in patients 80 years of age or older with cancer.
- Develop recommendations for the use of immune checkpoint inhibitors in patients 80 years of age or older with cancer.

Suarez-Almazor ME, Pundole X, Cabanillas G, et al. Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer. *JAMA Network Open.* 2022; 5:e225432.

Learning Objectives:

- Describe the study by Suarez-Almazor and colleagues of dual-energy X-ray absorptiometry (DXA) screening for low bone mineral density (BMD) in older men with prostate cancer who are initiating androgen deprivation therapy (ADT).
- Develop recommendations for the use of dual-energy X-ray absorptiometry (DXA) screening for low bone mineral density (BMD) in older men with prostate cancer who are initiating androgen deprivation therapy (ADT).

Meissner HC. Understanding vaccine safety and the roles of the FDA and the CDC. *N Engl J Med.* 2022; 386: 1638-45.

Learning Objectives:

- Describe the roles of the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) in ensuring vaccine safety, including the methods for evaluating safety and efficacy, pathways by which vaccine products are authorized or licensed, and factors taken into consideration in establishing vaccine recommendations.
- Explain to other healthcare professionals and patients the methods used by federal, state, and local agencies to ensure the safety and efficacy of vaccines for preventable diseases.

Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices – United States, 2022. *MMWR Morb Mortal Wkly Rep.* 2022; 71:109–117.

Learning Objectives:

- Describe the updated recommendations of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) for the use of the 20-valent pneumococcal conjugate vaccine (PCV20) and 15-valent pneumococcal conjugate vaccine (PCV15).
- Develop recommendations for the use of the 20-valent pneumococcal conjugate vaccine (PCV) and 15-valent pneumococcal conjugate vaccine (PCV15) in adults.

Ferdinands JM, Alyanek E, Reed C, Fry AM. Waning of influenza vaccine protection: exploring the trade-offs of changes in vaccination timing among older adults. *Clin Inf Dis.* 2020; 70(8):1550-9.

Learning Objectives:

- Describe the model developed by Ferdinands and colleagues to evaluate the impact of the timing of influenza vaccination on influenza-associated hospitalizations of older adults.
- Develop recommendations for the timing of influenza vaccination of older adults.

**Materials for this course will release 04/12/2023**

---

**Module 1B: Current Topics**

**ACPE#: 0204-9999-23-963-H01**

This module focuses on cancer management in older patients as well as contemporary issues related to vaccines.

Silber MH, Buchfuhrer MJ, Early CJ, et al. The management of restless legs syndrome: an updated algorithm. *Mayo Clinic Proc.* 2021; 96(7):1921-1937.

Learning Objectives:

- Describe the management of restless legs syndrome (RLS), including the updated algorithm from the RLS Foundation.
- Develop recommendations for the management of restless legs syndrome (RLS).

Deardorff WJ, Cenzer I, Nguyen B, Lee SJ. Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: A meta-analysis of randomized clinical trials. *JAMA Int Med.* 2022; 182:33-41.

Learning Objectives:

- Describe the meta-analysis by Deardorff and colleagues of studies of the time to benefit (TTB) from bisphosphonate therapy for the prevention of nonvertebral and other fractures in postmenopausal women with osteoporosis.
- Develop recommendations for the use of bisphosphonate therapy in postmenopausal women with osteoporosis taking into consideration the potential benefits and harms and life expectancy.

Li, L., Marozoff, S., Lu, N. et al. Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study. *Arthritis Res Ther.* 24:85 (2022).

Learning Objectives:

- Describe the study by Li and colleagues of tramadol compared with commonly prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) or codeine in older adults with osteoarthritis (OA).
- Develop recommendations for the treatment of osteoarthritis (OA) pain in older adults.

Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. *NEJM.* 2021; 385: 1268-79.

Learning Objectives:

- Describe the Strategy of Blood Pressure Intervention in Elderly Hypertensive Patients (STEP) study by Zhang and colleagues.
- Develop recommendations for the target systolic blood pressure (SBP) in older adult patients with hypertension.

Chen T, Shao F, Chen K, et al. Time to clinical benefit of intensive blood pressure lowering in patients 60 years and older with hypertension: A secondary analysis of randomized clinical trials. *JAMA Int Med.* 2022: 1657.

Learning Objectives:

- Describe the analysis by Chen and colleagues of the time to clinical benefit from the use of intensive blood pressure control instead of standard blood pressure control in older adult patients with hypertension.
- Develop recommendations for the target systolic blood pressure (SBP) in older adult patients with hypertension taking into consideration the potential benefits and harms and life expectancy.

**Materials for this course will release 04/12/2023**

---

McDonald EG, Wu PE, Rashidi B, et al. The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial. *JAMA Intern Med.* 2022; 182(3):265-273.

Learning Objectives:

- Describe the 2022 MedSafer study by McDonald and colleagues of electronic decision support for medication deprescribing in hospitalized older adults with polypharmacy.
- Develop recommendations for medication deprescribing interventions for hospitalized older adults with polypharmacy.

Bayliss EA, Shetterly SM, Drace ML, et al. Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians: The OPTIMIZE Pragmatic Cluster Randomized Trial. *JAMA Intern Med.* 2022; 182(5):534–542. doi:10.1001/jamainternmed.2022.0502.

Learning Objectives:

- Describe the Optimal Medication Management in Alzheimer Disease and Dementia (OPTIMIZE) study by Bayliss and colleagues of an intervention to increase patient and primary care clinician awareness of the potential to deprescribe unnecessary or risky medications in older adult outpatients with polypharmacy, dementia, or mild cognitive impairment (MCI), and additional chronic medical conditions.
- Develop recommendations for medication deprescribing strategies in the primary care setting for older adult outpatients with polypharmacy, dementia, or mild cognitive impairment (MCI), and additional chronic medical conditions.

### **Module 1C: Guideline Updates**

**ACPE#: 0204-9999-23-964-H01**

This module focuses on recent updates to guidelines for the management of benign prostatic hyperplasia, aspirin use for primary prevention of cardiovascular disease, coronary artery revascularization, and falls in adults with cardiovascular disease.

Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Part I - Initial work-up and medical management. *The Journal of Urology.* 2021; 206:806-817.

Learning Objectives:

- Describe the American Urological Association (AUA) guideline for the initial work up and medical management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH).
- Develop recommendations for the initial work up for or medical management of lower urinary tract symptoms (LUTS) in a patient with benign prostatic hyperplasia (BPH).

USPSTF. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2022; 327:1577-1584.

Learning Objectives:

- Describe the U.S. Preventive Services Task Force recommendation statement on aspirin use to prevent cardiovascular disease.
- Develop recommendations for the use of aspirin for primary prevention of cardiovascular disease.

**Materials for this course will release 04/12/2023**

---

Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. *J Am Coll Cardiol.* 2022; 79:e21-e129. Focus on sections: section 11 (Pharmacotherapy in patients undergoing PCI), section 13 (Pharmacotherapy in patients undergoing CABG), Section 14 (Pharmacotherapy in patients after revascularization).

Learning Objectives:

- Describe the 2021 guideline for coronary artery revascularization from the American College of Cardiology (ACC), American Heart Association (AHA), and Society for Cardiovascular Angiography and Interventions (SCAI).
- Develop recommendations for pharmacotherapy in patients undergoing percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) surgery, or revascularization.

Denfeld QE, Turrise S, MacLaughlin EJ, et al. Preventing and managing falls in adults with cardiovascular disease: a scientific statement from the American Heart Association. *Circ Cardiovasc Qual Outcomes.* 2022; 15:e000108.

Learning Objectives:

- Describe the American Heart Association scientific statement on preventing and managing falls in adults with cardiovascular disease
- Develop recommendations for the prevention and management of falls in adults with cardiovascular disease (CVD)

#### Faculty

**Alanna Breckenridge, PharmD, BCGP**

Transition of Care Clinical Pharmacist  
Northside Hospital Forsyth  
Cumming, Georgia

**Brooklyn Cobb, PharmD, BCPS**

Clinical Pharmacy Specialist, Ambulatory Care  
Memorial Hermann Southwest Hospital  
Houston, Texas

**Mary Kathryn Cozart, MEd, PharmD, BCPS, BCGP, BCACP**

Clinical Pharmacist Practitioner  
VA Tennessee Valley Healthcare System  
Clarksville, Tennessee

**Julianna Fernandez, PharmD, BCPS, BCGP**

Clinical Associate Professor  
University of Houston College of Pharmacy  
Houston, Texas

**Danielle Fixen, PharmD, BCGP, BCPS**

Assistant Professor, Department of Clinical Pharmacy  
University of Colorado Skaggs School of Pharmacy and  
Pharmaceutical Sciences  
Aurora, Colorado

**Rena Gosser, PharmD, BCPS**

Clinical Ambulatory Pharmacy Manager  
University of Washington Medicine - Harborview Medical  
Center  
Seattle, Washington, DC

**Jeannie Lee, PharmD, BCPS, BCGP, FASHP**

Assistant Dean - Student Services  
Associate Professor - Geriatrics, General Internal  
Medicine, and Palliative Care  
The University of Arizona  
Tucson, Arizona

**Ginah Nightingale, PharmD, MBA, BCOP**

Associate Professor, Department of Pharmacy Practice  
Jefferson College of Pharmacy  
Philadelphia, Pennsylvania

**Andrew Whitman, PharmD, BCOP**

Lead Clinical Pharmacist - Hematology/Oncology  
University of Virginia Health  
Department of Pharmacy Services

**Tasha Woodall, PharmD, BCGP, CPP**

Co-Director, MAHEC Center for Healthy Aging  
Asheville, North Carolina  
Associate Professor of Clinical Education  
UNC Eshelman School of Pharmacy

**Materials for this course will release 04/12/2023**

---

#### Content Matter Experts

**Snehal H. Bhatt, PharmD, AACC, BCPS-AQ Cardiology, FASHP\***

Professor of Pharmacy Practice Massachusetts College of  
Pharmacy and Health Sciences  
Framingham, Massachusetts

**Dana Carroll, PharmD, BCGP, BCPS, CDES\***

Clinical Professor  
Auburn University Harrison School of Pharmacy  
University of Alabama Family Medicine  
Auburn, Alabama

**Amie Taggart Blaszczyk, PharmD, BCGP, BCPS, FASCP\***

Professor and Division Head – Geriatrics  
Texas Tech University Health Sciences Center  
School of Pharmacy  
Lubbock, Texas

**Maria Shin, PharmD, BCGP, BCPS\***

Clinical Pharmacy Specialist in Internal Medicine  
Robley Rex Louisville Veterans Affairs Medical Center  
Louisville, Kentucky

**Douglas Slain, PharmD, BCPS, AQ-ID\***

Professor & Infectious Diseases Clinical Specialist  
West Virginia University  
Morgantown, West Virginia

#### Reviewers

Holly L. Byrnes, PharmD, BCPS  
Anna Jackson, PharmD, BCPS

#### Field Testers

Julia Bradshaw, PharmD, BCPS, BCGP  
Yali Brennan, PharmD, BCGS, CDCES  
Timothy Carbone, PharmD, BCGP, MBA  
Jeanette Cavano, PharmD, BCGP  
Kira Durr, PharmD, BCGP  
Ryan Feeney, PharmD, BCPS, BCGP  
Kirsten Gallo, PharmD, BCGP  
Kathy Grams, BPharm, PharmD  
Monica Healy, PharmD, BCGP  
Robert Hoel, PharmD, BCGP  
Megan Kaiser, PharmD, BCPS, BCGP  
Kevin Lazaruk, RPh, BCGP, BCMAS, CDP  
Bryan Mayfield, PharmD, BCGP  
Tracey Meade, PharmD, BCGP  
Katie Meyer, PharmD, BCPS, BCGP

John Minchak, PharmD, MBA, BCPS, BCGP  
Matthew Morrissey, PharmD, BCGP  
Christina Nunemacher, PharmD, BCGP  
Jennifer Peng, PharmD, BCGP  
Polina Plotkin, PharmD, BCACP, BCGP  
Megan Sculley, PharmD, BCGP, CDCES  
Eric Set, PharmD, APh, BCGP  
Yang-Yi Shemesh, PharmD, BCPS  
Garcia Simon-Clarke, PharmD, BCNP, BCGP, BCPS  
Irene Solorio, Pharm.D., BCGP  
Stephanie Stewart, PharmD, BCGP  
Anita Strong, RPh, BCGP  
John Tessarzik, PharmD, BCGP  
Melissa Tiedeman, PharmD, BCGP  
Rita Weiss, PharmD, JD, BCGP

#### Disclosures

In accordance with our accreditor's Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

**Materials for this course will release 04/12/2023**

---

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

**Methods and CE Requirements**

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

**System Technical Requirements**

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

**Development**

ASHP collaborates with ACCP on Geriatric Pharmacy activities.